Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
mepolizumab
|
| gptkbp:clinicalTrials |
Phase III
NCT02096585 NCT02414854 NCT02598981 NCT02928939 NCT02928952 chronic rhinosinusitis with nasal polyps |
| gptkbp:contraindication |
pneumonia
active infections anaphylaxis herpes zoster live vaccines hypersensitivity reactions hypersensitivity to mepolizumab increased eosinophils |
| gptkbp:date |
2015-11-04
|
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
monoclonal antibody
prescription only |
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| gptkbp:hasPopulation |
adults
children over 6 years |
| gptkbp:healthcare |
injection technique
recognizing side effects importance of adherence when to seek medical help |
| https://www.w3.org/2000/01/rdf-schema#label |
Nucala
|
| gptkbp:is_monitored_by |
lung function
symptom control eosinophil counts |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2015
|
| gptkbp:mandates |
severe asthma
eosinophilic asthma hypereosinophilia |
| gptkbp:manufacturer |
gptkb:GlaxoSmithKline
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:offers |
varies by region
|
| gptkbp:provides |
GINA guidelines
NHLBI guidelines NCCN_guidelines |
| gptkbp:route |
subcutaneous
|
| gptkbp:sideEffect |
fatigue
headache muscle pain back pain injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
IL-5
|
| gptkbp:triggerType |
IL-5 inhibition
|
| gptkbp:usedFor |
asthma
eosinophilic granulomatosis with polyangiitis |